Key facts
- Excellergy’s last known valuation is $122.2M.
- It has raised $79.8M; the latest was Early Stage VC ($72.2M) in Aug 2024.
- Notable investors include Samsara BioCapital, Red Tree Venture Capital, Decheng Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Excellergy
- ·The full record, as it builds
Funding rounds
No funding rounds for Excellergy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Excellergy
Developer of protein therapeutics designed to combat severe allergic diseases. The company offers specialized expertise in IgE biology and anti-IgE molecular pharmacology, enabling patients with severe allergies to experience improved quality of life.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2020
- Employees
- 7
- Website
- excellergy.com/
- Ownership
- Privately Held (backing)
Excellergy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Excellergy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Excellergy in its N-PORT filings yet. We sweep new filings monthly.